2018 DC Briefing

Cancer & Down Syndrome Explained at Amgen/Global Congressional Briefing

On September 14, 2018, Biotech powerhouse Amgen and the Global Down Syndrome Foundation (Global) hosted a first-in-kind Congressional Briefing attracting world-renowned cancer speakers from both the science and the medical fields. This important DC briefing attracted health staffers from both sides of the aisle, numerous families, and self-advocates. Attendees learned about the increased risk of leukemia and the decreased risk of solid tumor cancers for people with Down syndrome and how Congress and the NIH can support Down syndrome-Cancer research.

Key speakers included Joaquín Espinosa, Ph.D., the Executive Director of the Linda Crnic Institute for Down Syndrome and co-Leader of the Molecular Oncology Program at the University of Colorado; Michelle Sie Whitten, President & CEO of the Global Down Syndrome Foundation; John D. Crispino, Ph.D., Professor of Medicine (Hematology and Oncology) and Biochemistry and Molecular Genetics and Northwestern University; and Joan D. Morris, M.D., Global Development Research Clinical Medical Director at Amgen.

Photo Cred: Michael Campbell Photography

Learn more about the latest Down syndrome-Cancer research and how Global is lobbying Congress to get more funding from the NIH for these important discoveries.